recommendations may contribute to these high rates. [3][4][5] No statistical difference in discordance rates existed between EGDs that were referred by primary care physicians vs gastroenterologists. Possible explanations include the relatively recent guideline publication and potential selection bias for greater symptom severity among gastroenterologists. 6 Limitations included our short study duration and inability to capture patientdriven referrals, insurance data, and additional endoscopies performed at other institutions. A multidisciplinary approach of specialist prereview of open-access referrals, incorporation of appropriate indications in referral orders, and continued education may result in improved concordance with the evidence-based guidelines.
More steps need to be taken, including checklists before procedures, to review appropriate indications for use; substantive discussions with patients to obtain informed consent to comprehensively review expected benefits, risks, and costs as well as treatment alternatives; and better physician reimbursement policies are needed to provide sufficient financial support for these discussions between patients and their physicians. As patients and physicians grow increasingly aware of the need to promote evidence-based high-value health care, we need to develop the tools to make this care a reality in practice. Methods | We extracted the quarterly FDA Adverse Event Reporting System data files of AE reports received between January 1, 2004, and June 30, 2014. We excluded direct reports to the FDA (about 5%) in which drug manufacturers are not involved. Our final sample included only the initial reports (excluding follow-ups) characterized by the FDA as expedited, and therefore subject to the regulation requiring the reports to be submitted within 15 calendar days. Analysis was conducted from May 2014 to May 2015. The University of Minnesota Institutional Review Board determined that this study does not meet the regulatory definition of human subjects research. Our categorical outcome variable indicated whether the number of calendar days between the date the manufacturer received the report and the date the FDA received the same report from the manufacturer ("days to FDA") was: 15 days or fewer, 16 to 90 days, 91 to 180 days, or more than 180 days. We estimated a multivariable ordered logit model to examine the association between the categorical outcome variable and whether the AE involved patient death, adjusting for the number of unique drugs the patient was taking, the source of the report to the manufacturer (ie, consumer, physician, pharmacist, lawyer, or other), whether the report was electronically submitted, and patient age, sex, and weight. We included an indicator for the missing values of patient age, sex, and weight. To account for time trends, we included quarter and year indicators, and to account for systematic differences across manufacturers, we included indicators for manufacturers. We clustered standard errors at the drug level to account for correlation within drugs.
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Results | The study included 1 613 079 AE reports. KaplanMeier estimates show that 9.94% of reports (N = 160 383; 40 464 with patient death and 119 919 without patient death) were not received by the FDA by the 15-day threshold (Figure) . Results of the log-rank test rejected the equality of the survivor functions by patient death (P < .001). In multivariable analyses, patient death was associated with delayed reporting (Table) . A larger adjusted rate of events without patient death Survival estimates of the number of days between the date the manufacturer received the adverse event (AE) report and the date the US Food and Drug Administration (FDA) received the same report from the manufacturer. Log-rank, P < .001. A, Kaplan-Meier estimates from day 1 onward. B, Kaplan-Meier estimates from day 15 onward. 
